The cost effectiveness strategies for management of urinary tract infections: results from a randomised controlled trial by Turner, David et al.
RESEARCH
Cost effectiveness of management strategies for urinary
tract infections: results from randomised controlled trial
David Turner, principal research fellow in health economics,1 Paul Little, professor of primary care research,2
James Raftery, professor, director of NETSCC and Wessex Institute,1 Sheila Turner, senior research fellow,1
Helen Smith, chair of primary care,3 Kate Rumsby, research programme manager, Wessex Research
Practices Collaboration,2 Mark Mullee, director of the Research Design Service South Central and senior
lecturer in medical statistics,2 on behalf of the UTIS team
ABSTRACT
Objective To assess the cost effectiveness of different
management strategies for urinary tract infections.
Design Cost effectiveness analysis alongside a
randomised controlled trial with a one month follow-up.
Setting Primary care.
Participants 309 non-pregnant adult women aged 18-70
presenting with suspected urinary tract infection.
Interventions Patients were randomised to five basic
management approaches: empirical antibiotics,
empirical delayed (by 48 hours) antibiotics, or targeted
antibiotics based on either a high symptom score (two or
more of urine cloudiness, smell, nocturia, dysuria),
dipstick results (nitrite or leucocytes and blood), or
receipt of a positive result on midstream urine analysis.
Main outcomemeasureDuration of symptoms and cost of
care.
ResultsManagement with targeted antibiotics with
midstream urine analysis was more costly over the period
of one month. Costs for the midstream urine analysis and
dipstick management groups were £37 and £35,
respectively; these compared with £31 for immediate
antibiotics. Cost effectiveness acceptability curves
suggested that if avoiding a day of moderately bad
symptoms was valued at less than £10, then immediate
antibiotics is likely to be the most cost effective strategy.
For values over £10, targeted antibiotics with dipstick
testing becomes the most cost effective strategy, though
because of the uncertainty we can never be more than
70% certain that this strategy truly is the most cost
effective.
Conclusion Dipstick testing with targeted antibiotics is
likely to be cost effective if the value of saving a day of
moderately bad symptoms is £10 or more, but caution is
required given the considerable uncertainty surrounding
the estimates.
INTRODUCTION
Urinary tract infections are common in female patients
in general practice,1 and urine is the most frequently
received specimen in microbiology laboratories.
These common bacterial infections affect half of all
women at least once in their lives.2 Clinical manage-
ment strategies vary, with empirical antibiotics com-
monly used. Many practitioners, however, also use
urinary dipstick results and request analysis of mid-
stream urine samples. In over 62% of women present-
ingwith suspected urinary tract infection, the diagnosis
is laboratory confirmed.3 The use of dipsticks and clin-
ical scoring algorithms can potentially help to improve
the precision of diagnosis by improving the positive
predictive values.3 It is unclear what effects different
management strategies will have on the costs and cost
effectiveness. We carried out an economic evaluation
alongside a randomised controlled trial to investigate
the costs and cost effectiveness of the differentmanage-
ment strategies for urinary tract infection.
METHODS
Randomised controlled trial
General practitioners or practice nurses recruited
patients with suspected urinary tract infection, either
first time or recurrent, on presentation. The study
included 309 non-pregnant adult women aged 18-70.
The practitioner collected baseline symptoms, clinical
information, and demographic details. Patients com-
pleted a symptom diary for 14 days. Patients were ran-
domised to one of five management groups: empirical
antibiotic treatment; empirical delayed antibiotics; anti-
biotic targeted by symptom score; antibiotic according
to dipstick algorithm (nitrites or leucocytes and a trace
of blood); or midstream urine analysis with sympto-
matic treatment until culture and sensitivity results
were available and then antibiotics targeted accord-
ingly. Full details of this trial are given elsewhere.4
Costs
Costs were estimated from an NHS perspective and
included the recruitment consultation with the general
practitioner and all NHS contacts related to urinary
tract infection in a one month follow-up period. Costs
for the recruitment visit included the consumable costs
for midstream urine analysis and dipstick tests plus
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laboratory costs for the urine analysis. Consumable
and laboratory costs were those of the local NHS
trust. The recruitment consultation was costed with
national unit costs per minute based on the duration of
consultation.5 The time taken to explain and perform
the test was included within this consultation.
As we had no data on length of consultation for
39/309 patients (13%) and antibiotic use for 41/309
(13%), we imputed missing values using maximum
likelihood estimation for consultation time and a
regression method (with results constrained to be yes
or no) for antibiotic use (SPSS version 14). Original
data were checked to ensure that the means and stan-
dard errors of the estimates for the imputed variables
were equivalent (mean values within 1%) to those of
the originals. These two items were imputed as the
data relied on completion by the practitioner and we
had no a priori reason that it would be correlated with
patients’ characteristics and so would be unlikely to
bias results. Not imputing would have lost an addi-
tional 49 cases for the final analysis. For costing pur-
poses we assumed that antibiotics were prescribed
according to the study protocol—that is, trimethoprim,
costed as in the British National Formulary.6 We
obtained details of use of resources during follow-up
directly from the patient’s general practice notes. Con-
tacts with general practitioners during follow-up were
costed as a standard 10 minute consultation.5 Mid-
stream urine analysis and antibiotic use were recorded
and costedwithmethods described earlier. Referrals to
secondary care during follow-upwere included if there
was a reasonable probability of the referral being attri-
butable to urinary tract infections; thiswas done in con-
sultation with a clinical expert blind to management
strategy (PL). We used NHS reference costs.7 All
costs were estimated for the year 2005-6 in pounds
(£). No time discounting was required.
Analysis
Using Microsoft Excel and SPSS version 14, we ana-
lysed the 83% (257/309) of participants for whom we
had estimates of both effectiveness and follow-up costs.
The economic evaluationwas a cost effectiveness study
in terms of cost per day of moderate or severe
symptoms avoided. Symptom days were obtained
from the patient’s diary completed for the 14 days
after recruitment. To test the robustness of estimates
obtained we also estimated means using 1000 boot-
strap samples.8 9 Bootstrapping was also used to esti-
mate cost effectiveness acceptability curves (CEAC)
for the cost per day of moderate or severe symptoms
avoided.10
Scenario analysis
To investigate the potential cost per QALY of different
management strategies a scenario analysis used a utility
loss of 0.2894 for a day with urinary tract infection
symptoms.11 We also carried out a threshold analysis
to show the utility loss per day of symptoms required
to produce a cost per QALY ratio of between £20000
and £30000, the values used inNICE (National Institute
for Health and Clinical Excellence) decision making.12
RESULTS
The resources used by patients in the fivemanagement
groups varied as expected (table 1), with those in the
dipstick group requiring the longest consultation and
those in the empirical antibiotics group the shortest.
The frequency of antibiotic use and investigations
also varied as expected between management groups,
as did the costs at one month (range £30.70-£37.10)
(table 2). These costs were attributable mainly to the
initial consultation.
Management strategies were ranked by mean effec-
tiveness (table 3); differences between groups were
small. Three strategies were dominated (delayed anti-
biotics, symptom score, and midstream urine), mean-
ing some other strategy was both less costly and more
effective. The immediate antibiotics and dipstick
groups were not dominated and incremental results
are given for the dipstick group compared with the
immediate antibiotic group. Although no effect differ-
ences were significant in conventional (frequentist) sta-
tistics, current health economic practices combine
such data in cost effectiveness acceptability curves.
Cost effectiveness acceptability curves by strategy
(figure) indicate that if avoiding a day of symptoms is
valued at less than £10, the most cost effective strategy
Table 1 | Resource use by patients* with urinary tract infection according to allocation to management strategy group
Immediate antibiotics
(n=56)
Midstream urine
(n=46)
Dipstick
(n=42)
Symptom scores
(n=60)
Delayed antibiotics
(n=53)
Recruitment visit to general practice
Mean length (mins) 11.6 12.4 13.0 11.9 12.5
Midstream urine samples taken 15 40 16 20 8
Dipstick tests carried out 31 22 40 35 17
No (%) prescribed antibiotics 54 (96) 38 (83) 32 (76) 52 (87) 40 (75)
Reconsultations with general practitioner within 1 month
No of visits 6 9 6 8 6
Midstream urine sample taken 3 3 4 5 3
Prescribed antibiotics 4 7 5 7 5
Referred to secondary care 0 0 0 0 0
*Excluding 52 who did not have complete follow-up data
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is likely to be immediate antibiotics. For values over
£10, the dipstick strategy becomes the most cost effec-
tive, although given the uncertainty present we can
only ever be 70% certain that this strategy really is the
most cost effective. The scenario analysis produced an
incremental cost per QALY ratio of £12 100 for the
dipstick test compared with immediate antibiotics.
Threshold analysis indicated that a utility loss per day
of symptoms of between 0.117 and 0.175 produced a
cost per QALY of between £20 000 and £30 000.
DISCUSSION
All management strategies for urinary tract infection
have similar resource implications. The similarities in
cost are not surprising as the tests used in this study
have low costs and would entail only small changes to
the time practitioners would need to provide care for a
patient with a urinary tract infection. Therefore there is
no strong reason to prefer any particular management
strategy on the basis of costs. The duration of symp-
toms was similar between groups, with the dipstick
strategy being associated with the shortest duration of
symptoms.Comparedwith the groupgiven immediate
antibiotics, the dipstick strategy cost £10 per additional
day of symptoms avoided.
Strengths and limitations
The current study is based on a randomised controlled
trial with a rigorously developed dipstick algorithm
and clinical score. The studied group comprised
women in whom urinary tract infection was the sus-
pected diagnosis.13 They had similar characteristics to
national attending samples in the United Kingdom1 so
study results should be representative of routine clini-
cal practice. Data on resource was obtained from study
records or from general practitioners’ notes.
The cost effectiveness analysis shown here presents
estimates of the cost per day of symptoms avoided.
These results should be interpreted with caution
because of the lack of significance in the effectiveness
data.4 It is unclear why there were better outcomes in
the dipstick group than in the immediate group as use
of antibioticswas higher in the immediate group (96% v
76%). Those in the dipstick group, however, had less
severe symptoms.4 The improvement in the dipstick
group could be related to the security of feeling that
they know from dipsticks that they do or do not have
an infection.
We considered only costs related to the NHS; this
might miss important costs such as travel and time off
work, which might be relevant as 83% of the partici-
pants were aged under 60. We had details on time off
work or study for 146/257 women and of these 48/146
(33%) needed time off because of their infection. There
were no significant differences, however, between any
of the groups so it is unlikely that considering these
costs would have altered the results. Some additional
travel costs would have been associated with reconsul-
tations but these were low, with an average of 0.13
reconsultations during follow-up.
Our analysis excluded any benefits associated with
reducing the use of antibiotics, such as less antibiotic
resistance. Strategies that reduce use of antibiotics are
thus undervalued.14 The highest numbers prescribed
antibiotics were in the group prescribed immediate
antibiotics (table 1).
Table 2 | Mean (SD) costs (£) and effectiveness of management strategies for urinary tract infection
Immediate antibiotics Midstream urine Dipstick Symptom scores Delayed antibiotics
Recruitment visit:
General practice visit 25.5 (8.7) 27.3 (11) 28.6 (9.5) 26.2 (10.3) 27.4 (10.8)
Midstream urine 1.2 (1.9) 3.8 (1.5) 1.7 (2.1) 1.4 (2.1) 0.7 (1.6)
Dipstick 0.2 (0.2) 0.2 (0.2) 0.4 (0.1) 0.3 (0.2) 0.1 (0.2)
Antibiotics 1.0 (0.2) 0.8 (0.4) 0.8 (0.4) 0.9 (0.3) 0.7 (0.4)
Total 27.8 (9.1) 32.1 (11.1) 31.4 (9.8) 28.7 (10.2) 29.0 (11.2)
Follow-up at 1 month:
General practice visit 2.4 (6.9) 4.3 (8.8) 3.1 (9.2) 2.9 (8.6) 2.5 (8.3)
Midstream urine 0.2 (1) 0.3 (1.1) 0.4 (1.3) 0.4 (1.2) 0.2 (1)
Referred to secondary care 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Antibiotics 0.2 (0.9) 0.4 (1.4) 0.3 (1) 0.2 (0.8) 0.1 (0.4)
Total 2.8 (8.2) 5.0 (10.4) 3.9 (11) 3.5 (10.2) 2.9 (9.5)
Total cost in 1st month 30.6 (13.9) 37.1 (15) 35.3 (13.3) 32.3 (13.9) 31.9 (15.8)
Effectiveness (days of
moderate/severe symptoms)
3.63 (2.7) 4.17 (3.1) 3.14 (2.1) 3.92 (3.6) 3.92 (3.8)
Value of moderate/severe symptom days avoided (£)
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Comparison with other studies
There is limited evidence on the cost effectiveness of
differentmanagement strategies for urinary tract infec-
tion in primary care. Three studies used modelling to
examine similar questions. The literature identified is
either from the United States or the UK and hence the
values presented here use different currency unit and
cost years. To aid comparisonwe also present values in
2005-6 £ usingUK15 orUS16 inflation indicators and an
exchange rate of $1.78 to the £17; adjusted values are
given in brackets. All the studies found that immediate
(empirical) antibiotics were the least costly. A UK
based study of management of urinary tract infection
in general practice found that laboratory testing with
empirical antibiotics resulted in earlier resolution of
symptoms at a cost of £215 (£246) per day of symptoms
avoided compared with empirical antibiotics.18 A US
cost utility study found that compared with empirical
treatment a complete urinalysis cost $2964 per addi-
tional QALM (quality adjusted life month) and dip-
sticks cost $48 460 per QALM (equivalent to £25 682
and £419 894 per QALY, respectively).11 A further
study found that treatment for urinary tract infection
with accompanying over-the-counter dipstick test
cost between $5.50 and $1.97 (£4.14 and £1.48) per
day of symptoms avoided, depending on how effective
the dipstick was in directing treatment to those who
actually had a urinary tract infection.14 These results
are consistent with those presented here as they show
that tests can be associated with additional costs and
additional days of symptoms avoided.
Interpretation of results
Our analysis suggests that each additional day of symp-
toms can be avoided at a cost of about £10. A judgment
would therefore need to be made of whether the value
of avoiding days of moderate or severe symptoms
would exceed this. The scenario analysis we con-
structed suggested that if a day of symptoms was asso-
ciated with a utility loss of 0.2984 then the dipstick
strategy could generate extra QALYs at a cost per
QALYof around £12 000.This analysis shouldbe trea-
ted with caution, however, as the estimate of 0.2984
was not derived directly from patients. More informa-
tion on utility losses associated with urinary tract infec-
tion symptoms would be important in determining the
value of days of symptoms avoided and hence in
informing the care of affected patients.
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